Media coverage about BioScrip (NASDAQ:BIOS) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BioScrip earned a media sentiment score of 0.13 on Accern’s scale. Accern also gave news articles about the company an impact score of 45.9460281439035 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have effected Accern’s analysis:
- BioScrip Inc (BIOS) Given Average Recommendation of “Hold” by Analysts (americanbankingnews.com)
- BioScrip (BIOS) Downgraded by Zacks Investment Research (americanbankingnews.com)
- BioScrip, Inc. (NASDAQ:BIOS) – An Eye on Stock’s Liquidity – Nasdaq Journal (nasdaqjournal.com)
- BioScrip (BIOS) Loss Widens in Q4, ’18 View Holds Promise – Nasdaq (nasdaq.com)
A number of research analysts recently commented on BIOS shares. BidaskClub raised shares of BioScrip from a “hold” rating to a “buy” rating in a research report on Thursday, January 4th. SunTrust Banks set a $4.00 target price on shares of BioScrip and gave the company a “buy” rating in a research report on Thursday, December 21st. Craig Hallum reaffirmed a “buy” rating and issued a $3.50 target price on shares of BioScrip in a research report on Thursday, March 8th. Zacks Investment Research raised shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Wednesday, January 10th. Finally, ValuEngine raised shares of BioScrip from a “sell” rating to a “hold” rating in a research report on Thursday, November 30th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $3.45.
BioScrip (NASDAQ:BIOS) last issued its quarterly earnings data on Thursday, March 8th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.08) by ($0.07). The business had revenue of $182.50 million for the quarter, compared to the consensus estimate of $171.35 million. During the same quarter in the prior year, the firm earned ($0.06) earnings per share. The business’s revenue was down 24.0% compared to the same quarter last year. equities analysts anticipate that BioScrip will post -0.24 earnings per share for the current fiscal year.
BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.